ABM Therapeutics-- Chen Chen

Chen Chen

Postdoctoral Research Fellow, Texas A&M University

Experience in Sundia MediTech as CEO

Published over 110 research papers and Co-invented 24 US patents/patent applications

Projects: ABM

ABM's innovative research platform could revolutionize targeted-therapy for the treatment of various cancers and enhance immuno-therapy by comination of small molecules with biologics.

Indications: Research platform for the treatment of brain cancers and various related cancers

Book 1-on-1 meeting with founder：eventbank.cn/event/24006/register/​

AceLink Therapeutics-- Jerry Shen

Yuqiao (Jerry) Shen

Ph.D.; Chief Executive Officer; Co-founder

Dr. Shen brings more than 20 years of pharmaceutical experience with a focus on drug development for cancer, genetic diseases and rare diseases. Before founding AceLink in 2019, he was Executive Director at BioMarin Pharmaceutical, responsible for small molecule drug discovery and development. He joined BioMarin in 2010 when the company acquired LEAD Therapeutics, a small drug discovery company where he served as VP of Drug Discovery Biology.  Prior to LEAD Therapeutics, he served as VP of R&D at Applied Biomics, a protein biomarker research and service company that he co-founded. 

Founded in 2019, AceLink Therapeutics is an innovative biopharma startup focusing on developing safe and effective medicines to address human genetic diseases (including many rare diseases) with high unmet needs.

Indications: GBA gene mutation-associated Parkinson's disease

Book 1-on-1 meeting with founder：eventbank.cn/event/24007/register/​

Anji Pharmaceuticals-- Yiwei Zong

Yiwei Zong

Ph.D.in Biomedicine from the University of Pennsylvania and is a Chartered Financial Analyst.Yiwei Zong is an experienced investor and entrepreneur and leads the corporate strategy of Anji.He previously served as Partner of a life sciences VC fund,where he had led a number of high-return investments.He also brings Fortune 500 experience to operational planning and M&A activity.

Anji Pharma is focused on China's unmet clinical needs and will push the registration and commercialization of world-class drugs through in-licensing of China rights. Founding team is are all veterans of the industry that have led drugs discovery for multiple drug discovery and are very experienced in the R&D, operations, and investment of such leading industry players.

Indications: Metabolic disease

Book 1-on-1 meeting with founder：eventbank.cn/event/24008/register/​

Eubulus-- Sheldon Cao

Sheldon Cao

Received Bachelor's and Master's degress in Chemistry from Peking University in 1980's,then received his Ph.D.degree in Chemistry from the University of Konstanz in 1991.He has 30 years of management and pratical expertise in drug development.2 drugs he was responsible for have been approved by the FDA to enter the market,whlie several others have entered clinical trials

Eubulus delivers novel medicines that meet serious unmet medical needs through pivotal and rigorous scientific discovery.

Indications: Targeted enzymatic hydrolysis (TED) technology based drugs for treatment of cancer

Book 1-on-1 meeting with founder：eventbank.cn/event/24009/register/​

QureBio-- Xiangdong Qu

Xiangdong Qu

Master, Cornell University

Experience in Hengrui, Amgen, Baylor and MD Anderson Cancer Center, Columbia University College of Physician and Surgeons

~10 publications

Lead incubation project in Viva: Qiyu

Qiyu is committed to R&D of macromolecular innovative drugs. They has established a leading bilogical drug R&D platform and focus on the areas of tumor immunity, gastric cancer, asthma and other huge unmet needs.

Indications: Antibody drugs for autoimmune, cancer and metabolic diseases

Book 1-on-1 meeting with founder：eventbank.cn/event/24011/register/​

VersaPeutics-- Yimin Zou

Yimin Zou

Postdoctoral Fellowship at University of California, San Francisco and San Diego 

Ph.D. University of California, Davis and San Diego

~45 publications

Lead incubation project in Viva: VersaPeutics, Versachem

VersaPeutics, Inc is a new biotech startup based in San Diego California, devoted to finding treatment for disorders of the nervous system, such as spinal cord injury, traumatic brain injury and stroke. They are currently building a team of outstanding scientists and business talents to achieve these goals. 

Indications: Acute and recent spinal cord injury (SCI)

Book 1-on-1 meeting with founder：eventbank.cn/event/24013/register/​

VivaVision Biotech-- Wang Shen

Wang Shen

Ph.D., University of Pittsburgh

Experience in Abbott, Kanion, Amgen, Sunesis

Projects: Weimou, Weiqing

~80 publications

VivaVision is a premier topical drug research and development company. They focus on the areas of Ophthalmology (dry eye, glaucoma), Dermatology (eczema, psoriasis, alopecia areata) and Gastroenterology (Crohn's disease, ulcerative colitis).

Indications: Dry eye syndrome and chronic eczema skin disease in children

Book 1-on-1 meeting with founder：eventbank.cn/event/24014/register/​

Totient -- James Sietstra

James Sietstra

Co-Founder

AB in Government from Harvard College;

President of Seven Bridges Genomics from 2012-2018; led commercial launches, formed 15+ pharma partnerships, raised $120M+ in equity

capital, and invested in complementary technologies;

Serial entrepreneur, successfully exited last three businesses, which generated $900M in total revenue since founding.

• Early-stage biotech with fully human antibody library in oncology.

• The Totient Cancer Atlas is a machine learning-based engine trained by integrating and harmonizing the largest cancer genomics datasets in the world.

• Totient has reconstructed and filed patents across 285 fully human monoclonal antibodies sequenced from tumor activated plasma obtained from extraordinary cancer survivors. The program is based on systematic statistical evidence from a large patient cohort (10,000+ patients), as opposed to anecdotal case studies.

• Our technology enables unbiased antigen discovery yielding a mix of known and novel oncology targets including PD1, MAGEA3, NY-ESO-1, and IL20.

• Antibodies are expressed in HEK293 and screened against 14,788 human protein using a high throughput protein array. Candidates for advancement are high affinity and highly specific to their target antigen with minimal off target binding.

• Seeking strategic partners to co-develop antibodies in library and/or to provide additional datasets for AI-driven new antibody discovery.

Indications: Immuno-oncology

Book 1-on-1 meeting with founder：eventbank.cn/event/24165/register/​

Forkhead BioTherapeutics -- Hua Lin

Hua Lin

Co-Founder, Chief Scientific Officer

Completed her Ph.D. at the University of Michigan and was a Postdoc and Assciate Research Scientist at Columbia University before she went on to work as a Senior Resarch Biologist at Merk then as a Team Leader/Principal Resarch Scientist at Eli Lilly.

Forkhead has demonstrated the ability to use targeted inhibition of FOXO1 to transform cells in the gut into glucose-regulated, insulin-producing cells. They aim to exploit this discovery by developing an oral agent -- a Foxin™ pill -- to treat insulin-dependent diabetes by restoring normal insulin production, and normalizing glucose metabolism.

Indications: Treatment of insulin-dependent diabetes

Book 1-on-1 meeting with founder：eventbank.cn/event/24168/register/​

AmacaThera -- Michael Cooke

Michael Cooke

CEO

Completed his Ph.D. in at the University of Durham in controlling stem cell behaviour and then went on to do his postdoc at the University of Toronto. He has worked for Amacather for the since October 2015.

AmacaThera has developed a platform technology that can be used to sustain drug release. They are building out a productfor pain control to demonstrate efficacy of the platform. Collaborations are ongoing for the development of additional applications.

Indications: Sustained anesthetic product for post-surgical analgesia

Book 1-on-1 meeting with founder：eventbank.cn/event/24169/register/​

Proviva Therapeutics -- Harry Zhou

Harry Zhou

Founder, President & CEO

Ph.D., New York University

Postdoc., Univ. of Pennsylvania

Over 22 years of experience in R&D of biotherapeutics in metabolic, autoimmune/inflammatory diseases and cancer at Schering AG, Immunex, Amgen, GSK, Fabion Pharmaceuticals, and EMD Serono.

Founder of Fabion Pharmaceutical (USA, 2011)

Founder of EB1 Biotech (Israel, 2018)

Proviva Therapeutics, Inc., was founded in 2019 and it develops novel disease activatable biotherapeutics for treating autoimmune disorders and cancer. By leveraging highly robust, novel and proprietary discovery platforms, Proviva focuses on multispecific antibody and antibody fusion therapeutics with "First- or Best-in-class" potentials. PTX-001 (autoimmune) and PTX-101 (TME targeted mAb fusion of a tumor activatable IL-2 for Immuno-oncology) are two lead product candidates currently entering CMC development.  

What we offer: 

Research collaborations; Out-licensing of early stage product candidates

What we seek:

Talents in Discovery and Preclinical Research, Business Development, and Clinical Development.

Financial investments (Round A) to support 1) IND enabling studies, GMP manufacturing and FIH clinical trials of PTX-001 and PTX-101 and 2) Discovery Research. 

Indications: Cancer and infectious diseases

Book 1-on-1 meeting with founder：eventbank.cn/event/24171/register/​

Riparian Pharmaceuticals -- Will Adams

Will Adams

Will Adams is the CEO and co-founder of Riparian Pharmaceuticals. He launched the company from idea through moving several assets through lead optimization in a first-in-class therapeutic program today. He moved into biotech after his PhD studies in vascular biology at Brigham & Women's Hospital and the Harvard School of Engineering and Applied Sciences. Before that, he earned a M.S. in applied mathematics and B.S.in biomedical engineering from Harvard University.

Riparian Pharmaceuticals is discovering first-in-class therapeutics to promote vascular health and reverse endothelial dysfunction. Endothelial dysfunction is a primary driving force behind some of the most prevalent human diseases, such as atherosclerosis, peripheral arterial disease, diabetic microvascular complications and pulmonary arterial hypertension, among other vascular disorders.

Indications: Small molecule pathway activators for the treatment of pulmonary arterial hypertension and other vascular dysfunctions

Book 1-on-1 meeting with founder：eventbank.cn/event/24172/register/​

MEBIAS DISCOVERY -- Shariff Bayoumy

Shariff Bayoumy

Managing Director, Co-Founder

Former Head, Gene-to-Protein (J&J)

Unique expertise in GPCR expression, stabilization, and purification

17 years in biotech and pharma; 13 peer reviewed

papers; co-inventor on 2 patents

Mebias has developed a platform to discover novel biased GPCR drugs with an improved therapeutic index.

Indications: Pain

Book 1-on-1 meeting with founder： eventbank.cn/event/24215/register/​

Dover Lifesciences -- David Soohyun Chung

David Soohyun Chung

Doctor of Medicine, Harvard Medical School;

Created the first template and customizable website for pediatricians; Primary care pediatrician serving the Southeastern Massachusetts area; One of 128 Finalists in MassChallenge 2016;

Founder and CEO for Dover, clinical experience, a strong desire to bring treatments to patients with serious unmet medical needs, and the ability to attract a talented team with similar vision

Dover Lifesciences is exploiting a novel, genetically defined enzyme target to develop new treatments for NASH and obesity. The complete loss-of-function of the target protein in humans leads to unusual slimness with relatively mild metabolic disturbances. Fifty percent loss-of-function (carrier status) yields resistance to obesity. Metabolic profiling of carrier individuals reveals that these subjects generate a modestly elevated level of ketones with the typical overnight fast whereas most individuals do not generate appreciable amounts of ketones. Simply put, these individuals burn fat while they sleep. Dover is creating orally-available, tissue-targeted small molecules to inhibit the function of the target protein in overweight individuals with NASH. 

Book 1-on-1 meeting with founder：eventbank.cn/event/24216/register/​

Reglagene -- Richard Austin

Richard Austin

CEO

PhD in Organic Chemistry from the University of Texas;

MBA in Pharmaceutical Management from Drexel University in Philadelphia Pennsylvania;

23+ years Experience in pharmaceutical R&D at GSK and Sanofi;

A member of Tucson's Desert Angels

Reglagene is a preclinical stage therapeutics development company focused on the creation of new cancer treatments. It creates medicines that regain control of many of cancer's most notorious genes that drive resistance. It's lead program is a drug therapy that acts on the TERT gene, overexpressed in up to 90% of all tumor types, frequently in direct response to therapeutic intervention. The first clinical objective is the development of a once-daily oral agent to be administered adjunctively to counter resistance to hormone therapy in advanced prostate cancer. A second application is the identification of a therapy targeting the TERT gene for glioblastoma multiforme. 

Indications: Cancer

Book 1-on-1 meeting with founder：eventbank.cn/event/24217/register/​

Saverna Therapeutics AG -- Kamal Azzaoui

Kamal Azzaoui

CEO

PhD from the University of Orléans (France);

MAS from the University of Bern;

15 years experience in Novartis;

Consult for Elsevier, Openphact and Axxelis

Saverna significantly shortens time and cost for customers in the development of small molecule drugs for non-coding RNA-targets in inflammation, autoimmune diseases, cancer and infection via our proprietary drug discovery platform applying Nuclear Magnetic Resonance, fragment screening and machine learning technologies and processes.

Its strategic and operational set up is guided by the principles of lean organization, efficiency, highest professional standards, competences, experiences, targeted and selected outsourcing and collaboration networks with key universities, research & development institutions, production/marketing/sales and support organizations at global level. 

Indications: Immunological, lupus

Book 1-on-1 meeting with founder：eventbank.cn/event/24218/register/​

Bright Angel Therapeutics -- Dominic Jaikaran 

Dominic Jaikaran 

CEO

PhD and BSc from the University of Toronto;

MBA from Rotman School of Management;

15 years experience in biotechnology and finance;

Experience in MaRS Invovation as Director;

Experience in BDC Venture Capital as Principal;

Experience in Diversa Corporation (now BASF) as Staff Scientist

Bright Angel Therapeutics is a pre-clinical stage biotechnology company focused on the development of novel therapeutics for the treatment of drug-resistant and life-threatening fungal infections. Fungi infect billions and systemic infections kill ~1.5M people per year, as many as tuberculosis or malaria, yet only three major classes of antifungal drugs have been approved for the treatment of systemic infections to date. Resistance to all three classes has been observed in the clinic and is now a major impediment to effective treatment. We are designing novel drugs that target key regulatory proteins involved in fungal stress responses because it has become clear that intact fungal stress responses are essential for the emergence and maintenance of antifungal drug resistance. Bright Angel Therapeutics is headquartered in Toronto, Ontario, Canada.

Indications: The emergence and maintenance of antifungal drug resistance

Book 1-on-1 meeting with founder：eventbank.cn/event/24277/register/​

DTx Pharma -- Arthur Suckow

Arthur Suckow

Co-founder, CEO

BS from the University of Delaware;

PhD from University of California;

Experience in Johnson & Johnson, AstraZeneca and Regulus Therapeutics;

Extensive experience in fatty acid pharmacology;

Numerous awards including a Beckman Fellowship, NSF graduate research fellowship

DTx is developing a technology that addresses the 'Achilles heel' of RNA medicines and is founded on the idea that lipidation, the covalent conjugation of long-chain fatty acids (LCFAs) to AS or siRNA, could be leveraged to solve the drug delivery challenge. The founding team viewed LCFAs as a mechanism to enable delivery of RNA therapeutics as highly underexplored relative to the understanding of the way LCFAs interact with membrane proteins to get into cells and to the knowledge gained around the use of LCFAs to promote half-life extension from the successful development and commercialization of lipidated peptide therapeutics. Initial efforts to explore the therapeutic utility of this platform focus on ocular, muscular and CNS-related indications.

Indications: Ophthalmology, neuro-muscular

Book 1-on-1 meeting with founder： eventbank.cn/event/24278/register/​

Shanghai Epican Genetech -- Xingyu Lu

Xingyu Lu

Doctor Xingyu Lu, 31

CEO of Shanghai Epican Genetech Co., Ltd. 

studied from professor Chuan He at The University of Chicago

Awarded Shanghai Pujiang Talent

Epican was founded based on the epigenetics testing technology of professor he chuan's laboratory at the university of Chicago. Epican specializes in the research and development, production and service of molecular diagnosis (genetic diagnosis) products, and has a research and development team composed of world-class medical and molecular biology senior technical personnel, with independent intellectual property rights of patent inspection technology, database system, medical reporting system and business management system. 

Indications: Development of tumor epigenetic diagnostic technology

Book 1-on-1 meeting with founder： eventbank.cn/event/24279/register/​

AcuraStem -- Samuel Alworth 

Samuel Alworth 

CEO and Co-founder

MBA, MS Engineering University of Washington;

15+ years' broad experience in the life sciences covering entrepreneurship, product management, business development and R&D

Raised nearly $20M from investors and non-dilutive government R&D funding;

Expert in machine learning and image recognition

AcuraStem is a biotechnology company advancing neuroscience through patient-based drug discovery and development. AcuraStem's first small molecule drug candidate, AS-1, for amyotrophic lateral sclerosis (ALS or Lou Gehrig's disease) will enter clinical trials in early 2021, after which the company will focus the patient-based strategy on developing treatments for additional neurodegenerative diseases. Preclinical models of neurodegenerative diseases have not been predictive of clinical efficacy. AcuraStem's patient-based technology platform, iNeuroRx®, uses living neurons from patients to better discovery and develop new and highly effective treatments.

Indications: ALS

Book 1-on-1 meeting with founder： eventbank.cn/event/24419/register/​

Seraxis -- William Rust

William Rust

Chief Executive Officer and Founder

Stem cell and Type 1 diabetes scientific expert with 16 years experience in this field;

Earned 4 Excellence Awards, 3 government grants and 6 patents;

17 publications in leading scientific journals;

Forward thinker and highly motivated to finding a cure for diabetes;

Prior relevant experience: Novartis, Lonza, ATCC.

Seraxis is a privately held biotechnology company that has developeed a replacement cell therapy for insulin-dependent diabetes. Seraxis was founded in 2013 with a private equity placement to a group of Angel investors and VC. After demonstrating proof-of-concept, Seraxis completed a second round in 2015, including a mid-size pharma with the purpose of developing its cell therapy for the clinic. Seraxis has an experienced Board of Directors comprised of biotech and financial leaders, and a renowned international Scientific Advisory Board.

Indications: Diabetes

Book 1-on-1 meeting with founder： eventbank.cn/event/24420/register/​

Blue Oak -- Thomas Large

Thomas Large

CEO

Leadership experience in 

Eli Lilly, Sepracor, Sunovion;

Expert in systems and molecular neurobiology, CNS drug

discovery and early clinical development;

Successful partnering with large

pharma, biotech, CRO, academia and government;

Corporate, Board and Investor relations and M+A due diligence.

Blue Oak Pharmaceuticals is discovering the next generation of drugs for brain disorders. Our pioneering efforts over the past 12 years has validated a systems neurobiology strategy to discover first-in-class drugs. Our proprietary privileged chemotype platform is combined with high dimensional, in vivo behavioral assays and brain circuit imaging. First-in-class clinical candidates are advanced to early phase proof-of-principal studies using translational medicine biomarkers for brain circuit activity, for example EEG and phMRI. Clinical leads also identify novel pathways/targets to support best-in-class drug programs.

Indications: Neurological, bipolar depression

Book 1-on-1 meeting with founder: eventbank.cn/event/24477/register/​